Key result
In NVAF patients with ESRD or receiving dialysis, rivaroxaban was associated with similar risks of stroke or systemic embolism compared to apixaban (HR 1.18; 95% CI 0.53-2.63).
Why the study?
The comparative effectiveness and safety of rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease and/or receiving dialysis in routine practice needed evaluation.
Does rivaroxaban compared to apixaban reduce stroke, systemic embolism, or major bleeding in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis?
Cohort (n=2,623)
Yes
Does rivaroxaban compared to apixaban reduce stroke, systemic embolism, or major bleeding in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis?
Effect estimate: HR 1.18 (95% CI 0.53-2.63)
In real-world practice, rivaroxaban and apixaban demonstrate similar effectiveness and safety profiles in patients with non-valvular atrial fibrillation and end-stage renal disease.
No takes yet. Share an insight, caveat, or question.
May support either agent for NVAF with ESRD; leaves open need for randomized confirmation of comparative safety.
Miao et al. (2020) conducted a cohort in Non-valvular atrial fibrillation with end-stage renal disease and/or receiving dialysis (n=2,623). Rivaroxaban vs. Apixaban was evaluated on Stroke or systemic embolism (SSE) (HR 1.18, 95% CI 0.53-2.63). In NVAF patients with ESRD or receiving dialysis, rivaroxaban was associated with similar risks of stroke or systemic embolism compared to apixaban (HR 1.18; 95% CI 0.53-2.63).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: